6-Isopropyl-6-nor-lysergic acid diethylamide
From Wikipedia, the free encyclopedia
(Redirected from IP-LAD)
![]() |
|
Systematic (IUPAC) name | |
---|---|
(8β)-N,N-Diethyl-6-isopropyl-9,10-didehydroergoline-8-carboxamide
|
|
Clinical data | |
Routes of administration |
Oral |
Legal status | |
Legal status |
|
(verify) |
IP-LAD, known also as 6-isopropyl-6-nor-lysergic acid diethylamide, is an analogue of LAD developed by the team of David E. Nicols. In studies on mice, it was found to be approximately 40% the potency of LAD, compared to the 60% increase in potency seen with ETH-LAD and roughly equivalent potency in AL-LAD and PRO-LAD.
References[edit]
Hoffman, A. J.; Nichols, D. E. (1985). "Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". Journal of Medicinal Chemistry. 28 (9): 1252–1255. doi:10.1021/jm00147a022. PMID 4032428.
![]() |
This article about an organic compound is a stub. You can help Wikipedia by expanding it. |